Suvorexant for Opioid Use Disorder

Phase-Based Progress Estimates
Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center, Baltimore, MDOpioid Use Disorder+1 MoreSuvorexant - Drug
21 - 65
All Sexes
What conditions do you have?

Study Summary

This trial is investigating whether the orexin neurotransmitter system is linked to sleep disturbance and stress in opioid use disorder patients who are early in their recovery and on medication assisted treatment.

Eligible Conditions
  • Opioid Use Disorder
  • Sleep Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 21 days (collected over a seven-day period in weeks 1, 4, and 8 of the trial)

Week 1
Change in Perceived Stress Scale 4 (PSS-4) score
21 nights
Total Sleep Time
Total Wake Time After Sleep Onset

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Active Control

Non-Treatment Group

200 Total Participants · 2 Treatment Groups

Primary Treatment: Suvorexant · Has Placebo Group · Phase 2

ActiveComparator Group · 1 Intervention: Suvorexant · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebos · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 21 days (collected over a seven-day period in weeks 1, 4, and 8 of the trial)

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,092 Previous Clinical Trials
31,769,070 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,615 Previous Clinical Trials
47,117,921 Total Patients Enrolled
Andrew S Huhn, PhDPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
90 Total Patients Enrolled

Eligibility Criteria

Age 21 - 65 · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
What site did they apply to?
Man Alive Inc., Lane Treatment Center100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Phone Call100.0%
Most responsive sites:
  1. Man Alive Inc., Lane Treatment Center: < 48 hours

Frequently Asked Questions

Am I eligible to partake in this experiment?

"This clinical trial is in search of 200 individuals between the ages 21 to 65 who have been diagnosed with opioid use disorder. In order for participants to be accepted, they must meet these eligibility criteria." - Anonymous Online Contributor

Unverified Answer

Is Suvorexant a risk-free medication for users?

"There is preliminary data that suggests the safety of Suvorexant, therefore this medication received a score of 2." - Anonymous Online Contributor

Unverified Answer

What is the maximum capacity of people who can participate in this experiment?

"Affirmative, has evidence that this clinical experiment is actively seeking volunteers. It was initially posted on November 20th 2020 and recently updated on May 16th 2022. This trial requires 200 individuals to participate from 5 different sites." - Anonymous Online Contributor

Unverified Answer

Is this research available to people under thirty years of age?

"The eligibility criteria for this clinical trial dictates that participants should be between 21 to 65 years of age. Separately, there are 121 studies involving patients below the legal voting age and 504 studies which involve seniors above 65." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies that participants can fill in this clinical investigation?

"According to the data available on, this trial is presently recruiting participants; it was first posted in November 2020 and has been recently updated as of May 16th 2022." - Anonymous Online Contributor

Unverified Answer

Is there a precedent of Suvorexant being tested in clinical settings?

"Currently, 14 clinical trials are being conducted for Suvorexant with two in their final Phase 3. While the primary research hub is located in Silver Spring, Maryland, 71 other sites have been enlisted to run these studies." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.